SCHEMBL4081927

SCHEMBL4081927

CCCN(CCC)CCN1CCN(c2ncnc(N(c3ccc4nc(C)cc(N(C)C)c4c3)c3ccc4nc(C)cc(N(C)C)c4c3)n2)CC1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABCC1 P33527 1/20 0.34
NTSR1 P30989 5/20 0.33
TERT O14746 3/20 0.32
KDM4E B2RXH2 3/20 0.32
RAD52 P43351 2/20 0.32
HTT P42858 1/20 0.32
CARM1 Q86X55 2/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
LMNA P02545 2/20 0.30
TSHR P16473 2/20 0.30
ALDH1A1 P00352 2/20 0.30
HPGD P15428 1/20 0.30
GFER P55789 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
GLA P06280 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4076910 0.88 BRD4 (0.35) ABCC1NTSR1TERTCARM1
SCHEMBL4074853 0.86 HRH4 (0.40) TERTKDM4ERAD52HTTTSHR
SCHEMBL4081462 0.83 HTR1A (0.35) ABCC1TERTKDM4EMEN1KMT2A
SCHEMBL4082012 0.81 ACVR1 (0.37) TERTKDM4EMEN1KMT2ALMNA
SCHEMBL4081924 0.77 TERT (0.53) TERTKDM4ERAD52HTTLMNA
SCHEMBL4076923 0.71 TERT (0.50) TERTHTTMEN1KMT2ALMNA
SCHEMBL4073121 0.71 NTSR1 (0.36) NTSR1TERTHTTMEN1KMT2A
SCHEMBL4073596 0.71 POLB (0.41) TERTHTTMEN1KMT2ATSHR
SCHEMBL4081928 0.69 BRD4 (0.32) TERTKDM4ERAD52HTT
SCHEMBL4073298 0.69 TERT (0.40) ABCC1TERTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887873-B2 Triazine derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-05-03 US claimed
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent AVENTIS PHARMA S.A. (FR) 2003-05-08 US claimed
US-20090226411-A1 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS AVENTIS PHARMA S.A. (FR) 2009-09-10 US disclosed
US-7482352-B2 Chemical derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2009-01-27 US disclosed
US-6887873-B2 Triazine derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-05-03 US disclosed
US-20050070571-A1 Chemical derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-03-31 US disclosed
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent AVENTIS PHARMA S.A. (FR) 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent DNASE1L3, SERPINB1, BRDT ABCC1 207/4885NTSR1 3752/4885TERT 43/4885
US-20090226411-A1 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS DPYD, NTPCR, NME1 ABCC1 185/4885NTSR1 4398/4885TERT 196/4885
US-20050070571-A1 Chemical derivatives and their application as antitelomerase agents DPYD, NTPCR, NME1 ABCC1 185/4885NTSR1 4398/4885TERT 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.